AbbVie raises Skyrizi and Rinvoq estimates, predicts $31B in 2027 sales
The loss of Humira exclusivity was long expected to be a blow to AbbVie’s immunology dominance, but the Skyrizi-Rinvoq tandem keeps outpacing expectations. In its fourth-quarter and full-year 2024...
View ArticleCelltrion looks to buy US facilities to sidestep potential Trump tariffs
South Korean biopharma contract manufacturer Celltrion is considering acquiring US manufacturing sites to mitigate President Donald Trump’s potential tariffs on foreign-made pharmaceuticals. Trump is...
View ArticleDaiichi Sankyo taps new CEO, aims to build up ADC franchise
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently Daiichi’s chief operating officer. Before starting that role in 2023 ...
View ArticleAstraZeneca scraps plan to expand UK vaccine site
AstraZeneca has canceled its plans to expand its vaccine manufacturing site in Speke, UK, after the new UK government trimmed funding for the project, a company spokesperson confirmed to Endpoints...
View ArticleEngland agrees to pay for Vertex’s sickle cell disease gene therapy
Vertex Pharmaceuticals and the National Health Service in England have reached a payment deal making the gene-edited therapy Casgevy available to certain people with sickle cell disease. The NHS said...
View ArticleGenentech joins suits against STD clinics over 340B discounts
Genentech is the latest drugmaker to sue the federal government over STD clinics it says are wrongfully receiving discounts through the federal 340B program. The company claimed Friday that several...
View ArticleAbbVie executives bask in Skyrizi, Rinvoq successes as the drugs take up...
The reports of AbbVie’s demise have been greatly exaggerated. Gone are the worries of Humira competition and its monumental patent cliff. The “lack of a shiny object” in the pipeline is a ...
View ArticleRFK Jr. continues to evade questions on vaccines and autism
Robert F. Kennedy Jr.’s chances of becoming HHS chief likely hinge on one of his more controversial stances: that vaccines contribute to the development of autism. And in written responses to ...
View ArticleRFK Jr. hearings leave key GOP senator “struggling”; Drugmakers report Q4...
Welcome back to Endpoints Weekly, thanks for starting your weekend with us. This week’s news was dominated by Robert F. Kennedy Jr.’s confirmation hearings to be HHS Secretary, as Kennedy faced two...
View ArticleThermo Fisher to lay off 300 workers at two viral vector factories
Thermo Fisher Scientific is cutting 300 employees across two viral vector manufacturing facilities in Massachusetts, marking the second round of layoffs at those factories in the past few months. The...
View ArticleSenate Democrats criticize RFK Jr.'s divestment plans ahead of Tuesday vote
Democrats in the Senate Finance Committee are calling Robert F. Kennedy Jr.'s new divestment plans to his son "plainly inadequate" ahead of a Tuesday vote on whether to advance his nomination to lead...
View ArticleCharles River to shut down North Carolina pathology facility
Charles River Laboratories is permanently closing its pathology facility in Durham, NC, after determining it is no longer “a strategic fit,” a company spokesperson told Endpoints News in an email....
View ArticleBiogen's research chief talks China, neuropsychiatry and pipeline plan
Fresh off a reorganization, Biogen’s research leader Jane Grogan says the biotech has to “look outside the walls of the company” to avoid being left behind. In her first interview since then, she told ...
View ArticleNoom cuts coaches, staff as fewer sign up
Noom has laid off employees in coaching and customer service after its bet on prescribing GLP-1 drugs wasn't enough to offset losses from its original program, Endpoints News has learned. The job cuts...
View ArticleUS biosimilar 'void' spells trouble as biologic patent expirations loom,...
While 118 biologics are expected to lose patent protection in the US over the next decade, that $234 billion opportunity for biosimilar developers may not materialize because of several challenges,...
View ArticleGene-edited pig kidneys will be tested in more humans soon
The FDA has cleared two new requests to test gene-edited pig kidney transplantation, including a first clinical trial of the technology. United Therapeutics announced Monday that it received the...
View ArticleOmega Therapeutics nears bankruptcy filing, lays off workers
Omega Therapeutics anticipates filing for bankruptcy within the next week, the epigenomic medicines company said in a filing, a sudden end for a company that just a year ago signed an obesity...
View ArticleMerck pauses Gardasil shipments to China
Merck is pausing HPV vaccine shipments to China “until at least mid-year” as it grapples with lower demand for the shot. The company also withdrew its $11 billion sales target for Gardasil by 2030 as ...
View ArticleAstellas shakes up management despite impressive nine-month earnings
Astellas is reorganizing its management team, and while it doesn't involve a change at the top as Daiichi Sankyo announced last week, it could still have major repercussions for drug development at ...
View ArticleRegeneron will start delivering quarterly dividends 37 years into its existence
Regeneron Pharmaceuticals, one of the original and longest-standing biotech companies, is entering the dividends arena for the first time. The Tarrytown, NY-based drugmaker surprised the market Tuesday...
View Article